The Center for Placental Histotherapy, with more than 20 years of experience in the treatment of patients with dermatological conditions, has treated more than 4,000 patients in the last 5 years. In it you will be able to find a multidisciplinary team led by the Cuban researcher Prof. Dr. Carlos Miyares Cao will provide you with the most specialized care in conditions such as: vitiligo, psoriasis and alopecia. With medications extracted from the human placenta.
84% of patients with vitiligo and 78% of patients with psoriasis achieved a solution to their disease. In this institution specialized in dermatological disorders you will be able to finding a cure, stopping and training medical personnel in the aforementioned diseases, as well as such as postgraduate courses and exclusive medicines in the world.
In the 1970s, Cuba, through a trade agreement, exported 40 tons of human placenta annually to MERIUX Laboratories in France; At the same time, Dr. Carlos Miyares Cao, a Cuban specialist in Gynecology and Obstetrics and professor of Pharmacology at the School of Medicine of the University of Havana, when studying the metabolism of placentas kept alive in laboratory conditions, discovered: a substance with stimulating activity of skin pigmentation.
The successful use of this substance in our country in the treatment of the dermatological disease known as vitiligo determined In the years 80-82, exports of placenta to France were suspended when the national pharmaceutical industry began the production of the new medicine known as Melagenin for distribution in pharmacies by prescription. n optional.
In 1985, the first international care service for patients with vitiligo was created at the "Cira García" Central Clinic in Havana City under the responsibility of Dr. Carlos Miyares Cao himself. The influx of patients from countries close to Cuba (Mexico, Venezuela, Colombia, etc.) led to the establishment of the first health tourism system.
In 1986, as a consequence of the international repercussion caused by the new Cuban treatment against vitiligo thanks to the medicine obtained from the human placenta, the Council of State founded the Placental Histotherapy Center under the direction of Dr. Carlos Miyares Cao with the aim of expanding these investigations.
In 1987, the center's national and international clinical service was created, given the increase in the number of patients with vitiligo who requested care in Cuba with the new medication. Medical coverage begins to be provided to patients from more than 90 countries, as well as as it gives to those nationally affected by this disease.
From 1992 to 1994, the country's leadership assessed the need to build a plant to obtain various medications obtained from the human placenta, not only Melagenin, because the research carried out by Dr. Carlos Miyares Cao and his team at the Placental Histotherapy Center had managed to obtain useful medications for other pathologies and a line of highly effective cosmetics to slow down the cellular aging process.
Before the construction of the Center plant, these products were produced in the following way: Melagenin, Piloactive Lotion and Shampoo. of Placenta in facilities of the medical pharmaceutical industry, with the manufacturing, packaging and quality control units being separated, which made their increase and large-scale production difficult, while Coriodermina and the remaining cosmetics were produced in the Histotherapy Center's own research area with better technological conditions but with little productive capacity, which is why it was increasingly difficult to satisfy the growing demand. national and international of these placental derivatives.
This situation gives rise to the need to have a Plant with modern technology and high productive capacity which began with Its construction was carried out in 1991, in the Municipality of La Lisa, near the town of Valle Grande in the City of Havana, in charge of the ECOA-25 of the MICONS with a project attended directly by the Investment Directorate. of the Council of State.
The construction lasted 4 years, the investment area covers 26,000 square meters and consists mainly of two parallel buildings.
The main building contains the necessary equipment for the storage and thawing of placentas collected in the country's maternity hospitals; extraction and bioprocessing of the different placental derivatives mentioned above, as well as such as packaging and storage for subsequent distribution in the country or export.
The second building houses the Quality Control, Chemical, Microbiological and Biological laboratories and an area for the development of new technologies.
The approved workforce is 170 workers and its theoretical production capacity is 3,000 bottles per hour.
Medical Services Providers